Granules India Ltd 2025 IR
The report highlights Granules India Limited's performance and sustainability progress for the fiscal year 2024-25. During the year, the company expanded its large-scale formulation manufacturing at the Genome Valley facility and entered the peptide therapeutic space through the acquisition of Senn Chemicals. On the ESG front, the company achieved a 32.2% absolute reduction in Scope 1 and 2 emissions compared to the FY23 baseline and secured SBTi validation for its Net Zero targets. Additionally, the company was awarded a Gold rating by EcoVadis, placing it in the top 5% of participating companies globally.
Company: Granules India Ltd
Sector: Health Care
Country: India
Year: 2025
Type: IR
Pages: 209
Granules India Ltd
Integrated Annual Report
The report highlights Granules India Limited's performance and sustainability progress for the fiscal year 2024-25. During the year, the company expanded its large-scale formulation manufacturing at the Genome Valley facility and entered the peptide therapeutic space through the acquisition of Senn Chemicals. On the ESG front, the company achieved a 32.2% absolute reduction in Scope 1 and 2 emissions compared to the FY23 baseline and secured SBTi validation for its Net Zero targets. Additionally, the company was awarded a Gold rating by EcoVadis, placing it in the top 5% of participating companies globally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees